Epstein-Barr virus latent membrane protein (LMP)

Epstein-Barr virus latent membrane proteins, comprising LMP1, LMP2A, and LMP2B, are essential viral oncoproteins that orchestrate the transformation, survival, and persistence of EBV-infected cells [2, 10, 16]. LMP1 functions as a constitutively active mimic of the CD40 receptor, triggering critical intracellular signaling pathways such as NF-κB, MAPK, and PI3K/Akt to drive cell proliferation and prevent apoptosis [2, 13, 16]. LMP2A and LMP2B facilitate viral latency by mimicking B-cell receptor signals, which allows infected B cells to survive without normal surface receptor expression while inhibiting the transition into the lytic replication cycle [7, 14, 21]. These proteins are primary drivers in several malignancies, including nasopharyngeal carcinoma, Hodgkin lymphoma, and post-transplant lymphoproliferative disorder [8, 11, 17]. Therapeutic strategies focus on immunotherapies, notably tabelecleucel, an approved allogeneic T-cell therapy that specifically recognizes and destroys cells presenting LMP-derived antigens [1, 11, 22]. Beyond immunotherapy, research is targeting these proteins through therapeutic vaccines and experimental inhibitors of their cytoplasmic signaling domains to address refractory EBV-associated cancers [4, 12, 15].

Other names

Epstein-Barr virus membrane proteinLatent membrane protein 1Latent membrane protein 2LMP1LMP2ALMP2BBNLF1BNRF1

Adoptive immunotherapy utilizing allogeneic or autologous Epstein-Barr virus-specific cytotoxic T lymphocytes that target cells expressing latent membrane protein antigens and eliminate them via T-cell receptor-mediated apoptosis [1, 11, 22]. Small molecule inhibition (preclinical) aims to disrupt the signaling domains of the proteins to induce cell death in malignant cells [4, 13, 20].